Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
Status:
Recruiting
Trial end date:
2024-08-12
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and
clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients
with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors
harboring PIK3CA mutations, candidates to receive maintenance HP after first line treatment
for metastatic disease with a taxane plus HP